Table 2.
Population pharmacokinetic model development for escitalopram
| Covariate | Model | −2LL | Δ −2LL | P value | |
|---|---|---|---|---|---|
| 1 | Base model |
2729.78 | |||
| Univariate Forward Selection | |||||
| 1~1 (CL) | CYP2C19 Genotype | M1 | 2721.40 | −8.38 | < 0.05 |
| Age (Centered Power Model) | M2 | 2724.24 | −5.54 | < 0.05 | |
| Weight (Centered Power Model) | M3 | 2725.15 | −4.64 | < 0.05 | |
| BMI (Centered Power Model) | M4 | 2729.30 | −0.49 | > 0.05 | |
| Sex | M5 | 2748.44 | 18.66 | > 0.05 | |
| Race | M6 | 2726.60 | −3.18 | > 0.05 | |
| Site (Pittsburgh vs. Pisa) | M7 | 2719.78 | −10.01 | < 0.05 | |
| 1~2 (V) | Weight (Centered Power Model) | M8 | 2729.08 | −0.70 | > 0.05 |
| BMI (Centered Power Model) | M9 | 2725.93 | −3.85 | < 0.05 | |
| Age (exponential model) | M10 | 2729.69 | −0.09 | > 0.05 | |
| Site (Pittsburgh vs. Pisa) | M11 | 2728.42 | −1.36 | > 0.05 | |
| Stepwise Backward Elimination | |||||
| 2~1 | CL(Genotype+Age+Wgt)+V(BMI) | M12 | 2707.11 | ||
| Eliminate Weight from CL | M13 | 2711.23 | 4.13 | < 0.05 | |
| Eliminate Age from CL | M14 | 2712.83 | 5.72 | < 0.05 | |
| Eliminate Genotype from CL | M15 | 2715.02 | 7.91 | < 0.05 | |
| Eliminate BMI from V | M17 | 2712.65 | 5.54 | < 0.05 | |
| 3~1 | CL(Genotype+Age+Wgt+Site)+V(BMI) | M18 | 2703.79 | −3.32 | > 0.05 |
| final model | CL(Genotype+Age+Wgt)+V(BMI) | M12 | 2707.11 | ||